Biosceptre: Promise beyond cancer




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Biosceptre: Promise beyond cancer
Released on: October 24, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    nfP2X7 is a variant of the P2X7 transmembrane ligand gated ion channel, and has been identified and characterized by Biosceptre as a significant new oncology therapy target.
  • Summary
  • Participants
  • Company
nfP2X7 is a variant of the P2X7 transmembrane ligand gated ion channel, and has been identified and characterized by Biosceptre as a significant new oncology therapy target. Daniel Barton discusses with Fintan Walton how the absence in normal tissue, along with the breadth of its presence in cancer, means that nfP2X7 is a highly specific oncology biomarker and target, and promises to be relevant to the successful treatment of many types of cancer.
Daniel Barton is Director of Business Development for Biosceptre, working across strategy and delivery, and applying broad professional skills in legal, administration, product development and marketing. Daniels’ academic background is molecular biochemistry and intellectual property. He has founded, run, and sold start ups, held P&L and board reporting roles in listed companies, and led development teams, collaborated with research groups, and commissioned external and internal product development and production teams.
Biosceptre is a UK based biotech R&D business investigating and exploiting a promising new target for the treatment of cancer – nfP2X7. nfP2X7 is a variant of the P2X7 transmembrane ligand gated ion channel, and has been identified and characterized by Biosceptre as a significant new oncology therapy target. Its absence in normal tissue, along with the breadth of its presence in cancer, means that nfP2X7 is a highly specific oncology biomarker and target, and promises to be relevant to the successful treatment of many types of cancer. The target nfP2X7 is: highly specific to cancer cells (we have strong evidence indicating no cross reactivity in human) occurs across a broad range of cancers (nfP2X7 has been detected in +20 human tumor samples) constitutes a significant IP asset (Biosceptre has been awarded over 100 patents globally) Biosceptre has multiple programs in the pipeline that exploit the nfP2X7 oncology target via a range of modalities including antibody, vaccine, and topically. Each has the potential to be a blockbuster in the treatment of cancer either individually or in combination with other treatments. Biosceptres’ IP portfolio and expertise around the unique biology of the nfP2X7 target also has significant potential for application & licensing across advanced therapeutic technologies, diagnostic and veterinarian uses.